the positive side if elixia launch ?fails?, page-14

I add my appreciation, Jev, for your as usual considered & cogent posts.

From all the posts, we seem all to be agreed on the strategy - the cellulite cream launch to generate enough cash to fund the pharma; the point at issue will it go well enough to do this.

For clarity, Jev & others, might I define terms a little more closely. You refer to 'Revenue'. That is usually used to refer to turnover. In this discussion we're all plainly talking about 'net profit' or similar, ie. the profit available in cash terms to POH after retailers' margins (fairly hefty in this market and for a launch usually sexed up with promotional incentives, volume discounts, etc.) ongoing marketing, manufacturing & distribution costs . Retail turnover in the stores might have to be pushing $6-700k a week to achieve aims, perhaps?

A matter of months will give us the answer. Here's hoping!!

Whatever, I do find it comforting that I can see a credible fallback position in the event the outcome falls a bit short of expectations